AXT107 0.25 mg

DRUG2 trials

Sponsors

AsclepiX Therapeutics, Inc.

Conditions

Diabetic Macular Edema (DME)Neovascular Age-Related Macular Degeneration (nAMD)

Phase 1

Safety and Bioactivity of AXT107 in Subjects With Diabetic Macular Edema

TerminatedNCT04697758

AsclepiX Therapeutics, Inc.Diabetic Macular Edema (DME)

Start: 2020-12-10End: 2022-10-01Updated: 2024-03-22

Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration

TerminatedNCT04746963

AsclepiX Therapeutics, Inc.Neovascular Age-Related Macular Degeneration (nAMD)

Start: 2021-02-01End: 2022-10-01Updated: 2024-03-22